Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that mainly affects the synovial membrane, cartilage, and bone tissue, and is associated with progressive disability, systemic complications, and increased mortality [1]. Antibodies to citrullinated protein antigens (ACPAs) are biomarkers in the diagnosis of RA and active effectors in the development of this disease. The presence of these antibodies is related to the appearance of cardiovascular comorbidities independently of traditional risk factors [2].
